NSCLC comprises of 85% of lung cancer cases and is characterized by diverse gene mutations, including epidermal growth factor receptor (EGFR), B-Raf oncogene (B-RAF), and anaplastic lymphoma kinase (ALK) [2,3]. The gene discussed is ALK; the disease is lung carcinoma.